RVMD Company Profile and Key Details

Q: Who are the executives of RVMD?

Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. David S. ArringtonSenior Vice President of Investor Relations & Corporation AffairsMr. David L. Pompliano Ph.D.Founding Chief Scientific OfficerDr. Mark A. Goldsmith Ph.D.Chief Executive Officer, Pres & ChairmanMr. Jack AndersChief Financial OfficerMs. Margaret A. Horn J.D.Chief Operating OfficerDr. Stephen M. Kelsey FRC Path., FRCP, M.D.Pres of R&DMs. Xiaolin WangExecutive Vice President of Clinical Devel.Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board

NASDAQ : RVMD

Revolution Medicines

$141.81

-0.7-0.49%

At Close 4:00 PM

60.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Revolution Medicines, Inc. (RVMD) stock declined over -0.49%, trading at $141.81 on NASDAQ, down from the previous close of $142.51. The stock opened at $142.56, fluctuating between $140.53 and $144.61 in the recent session.

Stock Snapshot

142.51

Prev. Close

30.15B

Market Cap

140.53

Day Low

-19.95

P/E Ratio

-7.11

EPS (TTM)

-2.54

Cash Flow per Share

142.56

Open

212.6M

Number of Shares

144.61

Day High

84.8%

Free Float in %

12.93

Book Value

1.88M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 08, 2026	142.56	144.61	140.53	141.81	2.12M
May 07, 2026	148.80	149.79	142.08	142.51	2.43M
May 06, 2026	146.72	151.43	145.29	151.07	2.13M
May 05, 2026	148.66	149.87	144.26	147.21	3.32M
May 04, 2026	141.15	148.26	140.95	147.90	2.42M
Apr 30, 2026	141.43	144.29	138.75	144.12	2.28M
Apr 29, 2026	143.03	144.15	139.78	140.55	2.47M
Apr 28, 2026	146.22	150.00	141.61	144.83	5.47M
Apr 27, 2026	137.17	137.25	131.02	131.67	4.73M
Apr 23, 2026	141.79	143.94	133.05	134.48	4.27M
Apr 22, 2026	149.67	149.68	141.00	141.50	3.6M
Apr 21, 2026	147.00	149.36	143.17	148.90	2.31M
Apr 20, 2026	151.85	153.50	146.17	146.23	3.44M
Apr 17, 2026	149.48	151.14	145.52	148.63	4.71M
Apr 16, 2026	152.55	155.70	147.30	149.27	5.7M
Apr 14, 2026	136.50	148.00	134.66	147.01	7.94M
Apr 13, 2026	132.26	136.80	127.00	136.30	14.62M
Apr 10, 2026	97.03	97.23	94.63	96.43	1.97M
Apr 09, 2026	96.75	98.00	94.70	96.22	1.28M
Apr 08, 2026	98.99	99.00	95.80	96.75	1.2M

Contact Details

Redwood City, CA 94063

United States

https://www.revmed.com 650 481 6801

About Company

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Peers

ARGX

-5.14-0.65%

argenx SE$782.17 REGN

5.79+0.82%

Regeneron Pharmaceuticals, Inc.$714.89 UTHR

-4.24-0.74%

United Therapeutics Corporation$564.94 MDGL

-24.82-4.64%

Madrigal Pharmaceuticals, Inc.$510.04 VRTX

4.82+1.13%

Vertex Pharmaceuticals Incorporated$429.82 PRAX

-3.26-0.98%

Praxis Precision Medicines, Inc.$330.02 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

9.01+3.04%

Krystal Biotech, Inc.$305.71 ALNY

-0.86-0.29%

Alnylam Pharmaceuticals, Inc.$295.05 ASND

-7.48-3.04%

Ascendis Pharma A/S$238.66

Company Overview

Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $141.81 USD, losing -$0.70 (-0.49%) from the previous close of $142.51. The stock is currently mid-range between its 52-week high and low $34.00 and $155.70. With a market capitalization of about $30.15 billion, Revolution Medicines, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.41). Key stats such as the average daily volume over the past year has been around 2.93 million shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Revolution Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark A. Goldsmith, the company employs approximately 616 people and listed since February 13, 2020. Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.1%, SMA50 4.98%, SMA200 70.76%). The stock’s 14-day RSI is 53.97 (neutral), while the ATR of 4.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.95% below its high and over 250.19% above its low. Average 10-day trading volume of 2.45 million shares is in line with the 3-month average of 2.69 million, indicating normal recent market interest.

Valuation Metrics

Revolution Medicines, Inc. trades at a P/E ratio of -20.54, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 18.79 reflecting a rich premium to book value. The P/FCF stands at -28.22, also below market averages. Compared to sector medians, Revolution Medicines, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Revolution Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.18. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Revolution Medicines, Inc. generated EPS of -$5.18 over the past year. Five-year average earnings growth is -27.8%. Wall Street analysts project EPS growth of 6.14% annually over the next five years. The latest quarter delivered EPS of -$2.29. The next quarter is forecast at -$1.76. Next year's EPS is expected at $4.13. Analyst sentiment is bullish. Analyst rating data shows there are 47 Strong Buy ratings, 21 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $215.00 to $56.00. The high target offers 51.61% upside. The low target suggests -60.51% downside. The mean target is $107.59. This offers -24.13% upside. Revolution Medicines, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 06, 2026, missed forecasts by 25.14%. The prior quarter beat by 17.72%. Over the last six quarters, Apple has recorded several small beats. These include 10.89% in February 26, 2025.

Shareholding & Insider Activity

Revolution Medicines, Inc. has 186.93 million shares outstanding. The public float is 158.55 million shares, elevated short interest at 7.93% of float. This equals 13.93 million shares. The short ratio is 8.22 days. Institutional investors hold 97.81% of the float. Insiders own 1.83%. TEPPER ROBERT I holds 5.10 million shares, Schroeder Thilo has 760.87 thousand shares and Kelsey Stephen Michael has 295.40 thousand shares. Over the past six months, insider transactions show net selling. They sold 268.44 thousand shares across 26 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Revolution Medicines generated $11.58M in revenue, or $0.10 per share. Gross margin was 19.61%, operating margin -4207.12%, and net profit margin -3768.28%. Returns are negative, with ROA at -20.89% and ROE at -23.89%.
On valuation metrics, Revolution Medicines trades at a P/E of -20.54, P/S of 0.00 and P/B of 18.79. The current ratio is 6.80 and quick ratio is 6.80. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -6251.89 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -6.75.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Revolution Medicines posted revenue of $11.58M, down slightly from $35.38M in the prior quarter. Gross profit was $2.27M (margin 19.61%). Operating income was - $487.19M (margin -4207.1%). Net income was- $436.37M (EPS - $3.86).
The company ended the quarter with $1.85B in cash and short-term investments, a total debt of $87.94M, and net debt of - $608.20M. Total assets were $2.09B, with equity of $1.83B. Financials further reflected weakness, with operating cash flow of - $350.57M, free cash flow of - $358.30M, and capital expenditures of - $7.73M.

Price Forecast & Outlook

Our AI price prediction model suggests that Revolution Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.07%, with price expected at $160.35 by May 22, 2026, within a range of $144.32 to $176.39 3-Month Outlook: Projected rise of 65.25%, reaching $234.34 by August 06, 2026, with a range of $232.86 to $235.94. 1-Year Outlook: Projected gain of 18.67%, with price at $168.29 by May 07, 2027, within a range of $162.59 to $174.10.

Key Takeaways

Revolution Medicines, Inc. (NASDAQ:RVMD) shares are up 45.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Revolution Medicines, Inc. trading at a premium to the broader market with a P/E of -20.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $85.04, suggesting -40.03% downside. Our AI forecast model points to short-term strength (13.07% over two weeks), a medium-term rise (65.25% over three months), and a longer-term gain (18.67% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Revolution Medicines, Inc. (RVMD) stock price?

Revolution Medicines, Inc. (NASDAQ: RVMD) stock price is $141.81 in the last trading session. During the trading session, RVMD stock reached the peak price of $144.61 while $140.53 was the lowest point it dropped to. The percentage change in RVMD stock occurred in the recent session was -0.49% while the dollar amount for the price change in RVMD stock was - $0.70.

RVMD's industry and sector of operation?

The NASDAQ listed RVMD is part of Biotechnology industry that operates in the broader Healthcare sector. Revolution Medicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RVMD?

Dr. Michael A. Fischbach Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board
Mr. David S. Arrington
Senior Vice President of Investor Relations & Corporation Affairs
Mr. David L. Pompliano Ph.D.
Founding Chief Scientific Officer
Dr. Mark A. Goldsmith Ph.D.
Chief Executive Officer, Pres & Chairman
Mr. Jack Anders
Chief Financial Officer
Ms. Margaret A. Horn J.D.
Chief Operating Officer
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.
Pres of R&D
Ms. Xiaolin Wang
Executive Vice President of Clinical Devel.
Dr. Martin D. Burke M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Walter Reiher Ph.D.
Chief Information Officer
Dr. Kevan M. Shokat Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

How RVMD did perform over past 52-week?

RVMD's closing price is 317.09% higher than its 52-week low of $34.00 where as its distance from 52-week high of $155.70 is -8.92%.

How many employees does RVMD have?

Number of RVMD employees currently stands at 616.

Link for RVMD official website?

Official Website of RVMD is: https://www.revmed.com

How do I contact RVMD?

RVMD could be contacted at phone 650 481 6801 and can also be accessed through its website. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, United States.

How many shares of RVMD are traded daily?

RVMD stock volume for the day was 1.88M shares. The average number of RVMD shares traded daily for last 3 months was 2.93M.

What is the market cap of RVMD currently?

The market value of RVMD currently stands at $30.15B with its latest stock price at $141.81 and 212.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	616
Beta	1.01
Sales or Revenue	$11.58M
5Y Sales Change%	-0.815%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RVMD Company Profile and Key Details

Revolution Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Valuation Metrics

Earnings & Analyst Outlook